INTRODUCTION: The issue of resistance to antiplatelet therapy has raised many questions in the area of neurovascular diseases. The first objective of this work was to determine the prevalence of aspirin resistance in neurovascular patients with clinical non-responsiveness to aspirin treatment and a high-risk of atherothrombotic complications using two interpretable and independent methods (aggregation and PFA 100). The second objective was to find the correlation between both assays and to evaluate the results in groups at risk for various cerebrovascular diseases. MATERIAL AND METHODS: Laboratory tests of aspirin resistance were performed in 79 patients with clinical non-responsiveness to aspirin treatment suffering from neurovascular diseases. Patients were divided into the two groups: expected low risk for aspirin resistance due to the first manifestation of a neurovascular disease (n = 34) and expected high risk due to the second clinical manifestation of a neurovascular disease (n = 45). RESULTS: The prevalence of aspirin resistance in both groups combined as determined by the PFA-100 and CPG techniques were 50.6% and 17.7%, respectively. No correlation was found between the two techniques. CONCLUSIONS: No significant prevalence of aspirin resistance was demonstrated by either method despite the heterogeneous pathophysiological mechanisms. However, we are presently unable to provide an accurate opinion on the value of laboratory test result or routine monitoring in clinical neurology. and M. Vališ, D. Krajíčková, J. Malý, R. Malý, I. Fátorová, O. Vyšata, R. Herzig
Poruchy kortikálního vývoje a benigní tumory mozku jsou častou příčinou dlouhotrvající farmakorezistentní epilepsie u dětských i dospělých nemocných. Tito nemocní jsou operačně řešeni a následně sledováni v epileptochirurgických centrech. Progrese gradingu mozkových tumorů u nemocných s farmakorezistentní epilepsií je vzácným problémem a rozvoj maligního tumoru mozku u nemocných s malformacemi kortikálního vývoje mozku je publikován zcela výjimečně. Ve sdělení prezentujeme dvě kazuistiky nemocných s farmakorezistentní epilepsií s neočekávaným rozvojem maligního tumoru mozku. U jedné nemocné s chronickou epilepsií došlo k velmi časné progresi gradingu opakovaně histologicky verifikovaného nízkostupňového gliomu s finálním nálezem glioblastomu. U druhého nemocného byl popsán výjimečný rozvoj glioblastomu v terénu hemimegalencefalie., Malformations of cortical development and benign brain tumors are frequent causes of long lasting pharmacoresistant epilepsy in paediatric and adult patients. Such patients are surgically treated and subsequently followed in epileptosurgical centers. Tumor upgrading in patients with pharmacoresistant epilepsy is only rarely encountered and the development of malignant brain tumor in a patient with malformation of cortical development is an exception. The aim of the paper is to present two cases of patients suffering from intractable epilepsy with unexpected development of malignant brain tumor. There was upgrading of low grade glioma (verified by repeated biopsy sampling) in one patient with chronic epilepsy with final diagnosis glioblastoma multiforme. An exceptional development of glioblastoma in hemimegalencephalic hemisphere was described in the second patient., Jan Chrastina, Dušan Hrabovský, Markéta Hermanová, Petr Burkoň, Milan Brázdil, Zdeněk Novák, and Literatura
In the department of coloproctology of NORC MH RUz 17 patients with disseminated forms of colorectal cancer was made the study of oncogenes and complex treatment by 2 protocols using FOLFOX4 regime and FOLFIRI regime. In second protocol there used 2 sessions of endolymphatical polychemotherapy FOLFOX4 regime against EHFhyperthermia. All patients were performed additional investigations directed to study the presence of multiple drug resistance in them where definition of р53, bcl2 oncogene expression. In our observations we followed resistance to FOLFOX4 scheme in 4 patients, and to FOLFIRI scheme in 2 cases. In our studies hyperexpression of oncoproteine р53 was correlated with the effect of conducted therapy whereas hyperexpr, Navruzov S. N., Abdujapparov S. B., Pulatov D. A., Islamov H. D., Matniyazova Sh. Ya., Akbarov E. T., and Literatura